64 related articles for article (PubMed ID: 20113845)
1. High sensitivity of BRCA1-associated tumors to cisplatin monotherapy: report of two cases.
Moiseyenko VM; Protsenko SA; Brezhnev NV; Maximov SY; Gershveld ED; Hudyakova MA; Lobeiko OS; Gergova MM; Krzhivitskiy PI; Semionov II; Matsko DE; Iyevleva AG; Sokolenko AP; Sherina NY; Kuligina ESh; Suspitsin EN; Togo AV; Imyanitov EN
Cancer Genet Cytogenet; 2010 Feb; 197(1):91-4. PubMed ID: 20113845
[No Abstract] [Full Text] [Related]
2. Pharmacogenetics of breast cancer: toward the individualization of therapy.
Chang JC; Hilsenbeck SG; Fuqua SA
Cancer Invest; 2009 Aug; 27(7):699-703. PubMed ID: 19637041
[No Abstract] [Full Text] [Related]
3. Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer.
Steinmann D; Bremer M; Rades D; Skawran B; Siebrands C; Karstens JH; Dörk T
Br J Cancer; 2001 Sep; 85(6):850-8. PubMed ID: 11556836
[TBL] [Abstract][Full Text] [Related]
4. HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry.
Quenneville LA; Phillips KA; Ozcelik H; Parkes RK; Knight JA; Goodwin PJ; Andrulis IL; O'Malley FP
Cancer; 2002 Nov; 95(10):2068-75. PubMed ID: 12412159
[TBL] [Abstract][Full Text] [Related]
5. Methylation of the BRCA1 gene in sporadic breast cancer.
Dobrovic A; Simpfendorfer D
Cancer Res; 1997 Aug; 57(16):3347-50. PubMed ID: 9269993
[TBL] [Abstract][Full Text] [Related]
6. Allelic imbalance and microsatellite instability in BRCA1 associated breast and ovarian tumors.
van der Looij M; Papp J; Sztán M; Pulay T; Elfadil I; Besznyak I; Tóth J; Devilee P; Oláh E
Int J Oncol; 2001 Apr; 18(4):775-80. PubMed ID: 11251173
[TBL] [Abstract][Full Text] [Related]
7. Novel somatic mutations in the BRCA1 gene in sporadic breast tumors.
Janatova M; Zikan M; Dundr P; Matous B; Pohlreich P
Hum Mutat; 2005 Mar; 25(3):319. PubMed ID: 15712267
[TBL] [Abstract][Full Text] [Related]
8. Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer.
Rhiem K; Wappenschmidt B; Bosse K; Köppler H; Tutt AN; Schmutzler RK
Clin Oncol (R Coll Radiol); 2009 Aug; 21(6):448-50. PubMed ID: 19249193
[TBL] [Abstract][Full Text] [Related]
9. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
Gong Y; Booser DJ; Sneige N
Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
[TBL] [Abstract][Full Text] [Related]
10. Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk.
Bean GR; Ibarra Drendall C; Goldenberg VK; Baker JC; Troch MM; Paisie C; Wilke LG; Yee L; Marcom PK; Kimler BF; Fabian CJ; Zalles CM; Broadwater G; Scott V; Seewaldt VL
Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):50-6. PubMed ID: 17220331
[TBL] [Abstract][Full Text] [Related]
11. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.
Manié E; Vincent-Salomon A; Lehmann-Che J; Pierron G; Turpin E; Warcoin M; Gruel N; Lebigot I; Sastre-Garau X; Lidereau R; Remenieras A; Feunteun J; Delattre O; de Thé H; Stoppa-Lyonnet D; Stern MH
Cancer Res; 2009 Jan; 69(2):663-71. PubMed ID: 19147582
[TBL] [Abstract][Full Text] [Related]
12. [Breast carcinoma in accessory gland: a case report].
Sivelli R; Del Rio P; Arcuri MF; Corcione L
G Chir; 2002 May; 23(5):179-80. PubMed ID: 12228967
[TBL] [Abstract][Full Text] [Related]
13. Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report.
Burness ML; Obeid EI; Olopade OI
Clin Breast Cancer; 2015 Apr; 15(2):e155-8. PubMed ID: 25445425
[No Abstract] [Full Text] [Related]
14. ERBB2 and MYC alterations in BRCA1- and BRCA2-associated cancers.
Palacios J; Honrado E; Cigudosa JC; Benítez J
Genes Chromosomes Cancer; 2005 Feb; 42(2):204-5; author reply 206. PubMed ID: 15543618
[No Abstract] [Full Text] [Related]
15. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations.
Tirkkonen M; Johannsson O; Agnarsson BA; Olsson H; Ingvarsson S; Karhu R; Tanner M; Isola J; Barkardottir RB; Borg A; Kallioniemi OP
Cancer Res; 1997 Apr; 57(7):1222-7. PubMed ID: 9102202
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer.
Seo JH; Cho DY; Ahn SH; Yoon KS; Kang CS; Cho HM; Lee HS; Choe JJ; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS; Son GS; Lee JB; Koo BH
Hum Mutat; 2004 Oct; 24(4):350. PubMed ID: 15365993
[TBL] [Abstract][Full Text] [Related]
17. Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma.
Hartman AR; Daniel BL; Kurian AW; Mills MA; Nowels KW; Dirbas FM; Kingham KE; Chun NM; Herfkens RJ; Ford JM; Plevritis SK
Cancer; 2004 Feb; 100(3):479-89. PubMed ID: 14745863
[TBL] [Abstract][Full Text] [Related]
18. Histopathological criteria and selection algorithms for BRCA1 genetic testing.
Gadzicki D; Schubert A; Fischer C; Milde S; Lehmann U; Steinemann D; Lück HJ; Kreipe H; Schlegelberger B
Cancer Genet Cytogenet; 2009 Mar; 189(2):105-11. PubMed ID: 19215791
[TBL] [Abstract][Full Text] [Related]
19. BRCA-associated breast cancer: absence of a characteristic immunophenotype.
Robson M; Rajan P; Rosen PP; Gilewski T; Hirschaut Y; Pressman P; Haas B; Norton L; Offit K
Cancer Res; 1998 May; 58(9):1839-42. PubMed ID: 9581822
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin plus vinorelbine (PVn) as a salvage regimen for refractory breast cancer.
Chehal A; Taher A; Khalil M; Shamseddine A
Breast; 2004 Oct; 13(5):421-4. PubMed ID: 15454199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
